1.73

1.70% -0.03

After Hours: 1.90 0.17 +9.83%

Inhibikase Therapeutics Inc (IKT)

Overview News Price History Financials Discussions Forecast Stock Split

Inhibikase Therapeutics Inc stock is currently priced at $1.73, with a 24-hour trading volume of 46,035. It has seen a -1.70% decreased in the last 24 hours and a -18.78% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.81 pivot point. If it approaches the $1.64 support level, significant changes may occur.

Previous Close:

$1.76

Open:

$1.76

24h Volume:

46,035

Market Cap:

$11.20M

Revenue:

Net Income/Loss:

$-19.13M

P/E Ratio:

-0.4149

EPS:

-4.17

Net Cash Flow:

$-18.21M

1W Performance:

+32.06%

1M Performance:

-18.78%

6M Performance:

+96.59%

1Y Performance:

+162.12%

1D Range:

$1.715

$1.8844

52W Range:

$0.5605

$3.82

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Name

Inhibikase Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

678-392-3419

Address

3350 Riverwood Parkway SE, Suite 1900, Atlanta

Employee

Twitter

Next Earnings Date

2024-06-07

Latest SEC Filings

IKT's Discussions on Twitter

Inhibikase Therapeutics Inc Stock (IKT) Latest News

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Earnings call: Inhibikase Therapeutics reports on drug trials progress - Investing.com South Africa

Investing.com South Africa

Earnings call: Inhibikase Therapeutics reports on drug trials progress - Investing.com India

Investing.com India

Inhibikase Therapeutics Inc Inc. (IKT) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

The InvestChronicle

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity - GlobeNewswire

GlobeNewswire

IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024 - MSN

MSN

Inhibikase Therapeutics Inc Stock (IKT) Financials Data

Inhibikase Therapeutics Inc (IKT) Net Income 2024

IKT net income (TTM) was -$19.13 million for the quarter ending September 30, 2023, a -1.67% decrease year-over-year.

Inhibikase Therapeutics Inc (IKT) Cash Flow 2024

IKT recorded a free cash flow (TTM) of -$18.21 million for the quarter ending September 30, 2023, a -1.80% decrease year-over-year.

Inhibikase Therapeutics Inc (IKT) Earnings per Share 2024

IKT earnings per share (TTM) was -$3.99 for the quarter ending September 30, 2023, a +10.14% growth year-over-year.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor to treat Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. It has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.